Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JNCE
Previous Symbol
CUSIPN/A
Phone857-259-3840
Debt
Debt-to-Equity RatioN/A
Current Ratio3.07
Quick Ratio3.07
Price-To-Earnings
Trailing P/E Ratio-6.19
Forward P/E Ratio-3.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.64 million
Price / Sales1.61
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.18 per share
Price / Book0.68
Profitability
EPS (Most Recent Fiscal Year)($0.57)
Net Income$-16,440,000.00
Net Margins-59.74%
Return on Equity-29.58%
Return on Assets-13.65%
Miscellaneous
Employees112
Outstanding Shares32,700,000
Market Cap$120.67 million
OptionableOptionable
Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions
What is Jounce Therapeutics' stock symbol?
Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."
How were Jounce Therapeutics' earnings last quarter?
Jounce Therapeutics Inc (NASDAQ:JNCE) released its earnings results on Tuesday, November, 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.34) by $0.11. The firm earned $14.53 million during the quarter, compared to analyst estimates of $12.80 million. Jounce Therapeutics had a negative net margin of 59.74% and a negative return on equity of 29.58%. View Jounce Therapeutics' Earnings History.
When is Jounce Therapeutics' next earnings date?
What guidance has Jounce Therapeutics issued on next quarter's earnings?
Jounce Therapeutics updated its FY 2018 earnings guidance on Tuesday, November, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $50-60 million, compared to the consensus revenue estimate of $56.46 million.
What price target have analysts set for JNCE?
6 equities research analysts have issued 1-year price objectives for Jounce Therapeutics' shares. Their predictions range from $10.00 to $20.00. On average, they expect Jounce Therapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 268.3% from the stock's current price. View Analyst Price Targets for Jounce Therapeutics.
What is the consensus analysts' recommendation for Jounce Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.
Has Jounce Therapeutics been receiving favorable news coverage?
Media headlines about JNCE stock have trended very negative on Saturday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Jounce Therapeutics earned a media sentiment score of -3.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Jounce Therapeutics' key competitors?
Some companies that are related to Jounce Therapeutics include Replimune Group (REPL), PDL BioPharma (PDLI), Mesoblast (MESO), CASI Pharmaceuticals (CASI), Translate Bio (TBIO), Cellular Biomedicine Group (CBMG), Krystal Biotech (KRYS), La Jolla Pharmaceutical (LJPC), Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Nightstar Therapeutics (NITE), Agenus (AGEN), Gamida Cell (GMDA), Surface Oncology (SURF) and Sutro Biopharma (STRO).
Who are Jounce Therapeutics' key executives?
Jounce Therapeutics' management team includes the folowing people:
- Dr. Richard Murray, Pres, CEO & Director (Age 59)
- Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 53)
- Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 58)
- Dr. James P. Allison, Founder
- Dr. Thomas F. Gajewski, Founder
When did Jounce Therapeutics IPO?
(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.
Who are Jounce Therapeutics' major shareholders?
Jounce Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (6.76%), BlackRock Inc. (4.45%), Vanguard Group Inc. (2.37%), Vanguard Group Inc (2.37%), JPMorgan Chase & Co. (1.35%) and JPMorgan Chase & Co. (1.35%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Celgene Switzerland Llc, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.
Which major investors are selling Jounce Therapeutics stock?
JNCE stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, FMR LLC and Alambic Investment Management L.P.. Company insiders that have sold Jounce Therapeutics company stock in the last year include Barbara Gayle Duncan, Elizabeth Trehu, Kimberlee C Drapkin and Richard /Ca/ Murray. View Insider Buying and Selling for Jounce Therapeutics.
Which major investors are buying Jounce Therapeutics stock?
JNCE stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Bridgeway Capital Management Inc., Man Group plc, Renaissance Technologies LLC, Dimensional Fund Advisors LP, GSA Capital Partners LLP and Russell Investments Group Ltd.. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc, Hugh M Cole and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.
How do I buy shares of Jounce Therapeutics?
Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jounce Therapeutics' stock price today?
One share of JNCE stock can currently be purchased for approximately $3.53.
How big of a company is Jounce Therapeutics?
Jounce Therapeutics has a market capitalization of $120.67 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe.
What is Jounce Therapeutics' official website?
How can I contact Jounce Therapeutics?
Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.
MarketBeat Community Rating for Jounce Therapeutics (NASDAQ JNCE)
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
